|
|

IN3 events bring together early/mid/late-stage, medical technology innovators with investors, venture capitalists, and business development executives - all in a single forum. Network with the biggest, medical device dealmakers in financing, partnering, and M&A!
Aciont, Inc.
Non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration.
-
Aerolase
Aerolase is a commercial stage company that has developed, manufactures and markets the LightPod® platform technology of unique, proprietary (protected by 5 U.S. patents), portable high power lasers for use in aesthetic and dermatological applications including wound healing and onychomycosis.
-
Aura Medsystems, Inc.
Aura’s Light activated Soft Tissue Repair system obviates the need for implanting sutures, staples, and glues thus allowing the body to repair and heal itself.
BioSculpture Technology, Inc.
BioSculpture Technology, Inc. addresses the vast liposuction and obesity markets with fully commercially saleable, FDA-approved, proprietary medical devices and technologies protected by 15 issued US and international patents and 8 registered trademarks.
CardioInsight Technologies Inc.
CardioInsight is developing the first non-invasive, real-time, beat-to-beat simultaneous mapping and localization solution for the treatment of cardiac arrhythmias and heart failure.
Cardiox Corporation
Patented a highly accurate, minimally invasive, automatic, and continuous system to measure and monitor cardiac output, total circulating blood volume, and endogenous blood ammonia levels.
CeQur, Ltd.
CeQur's lead product candidate is a small, wearable insulin delivery device that delivers both basal and bolus doses subcutaneously. Its simple and discrete design enables patients to more easily comply with insulin regimens and experience the benefits of intensive insulin therapy.
Chesson Labs
All of Chesson Labs products cleared for market and in development are based on this patented and patent-pending polymer formulation.
ClearView Patient Technologies
ClearView Patient Safety Technologies’ patented Flash Passive Safety™ technology reveals visible blood flow at the instant of vein penetration without activation or additional instruction. Its technology offers a universal solution that is simple and achieves reliable passive, optical venipuncture control.
-
CytoSorbents, Inc.
CytoSorb™ is a proprietary blood purification resin in clinical trials to treat severe sepsis or “overwhelming infection” by reducing cytokine storm; a major cause of organ failure and death in sepsis.
Elemé Medical
Elemé Medical is a commercial stage medical aesthetics company providing market-leading proprietary body shaping technologies. The Company has launched two devices: SmoothShapes® and SmoothShapes® XV.
-
GeneEx, Inc.
GeneEx is developing rapid, point-of-care saliva tests for infectious diseases capable of detecting virulence markers produced only during active infections.
-
Kerecis Limited
Novel tissue regeneration product for chronic wounds and hernia repair. Its patent pending fish skin derived material improves upon current human and porcine technologies through improved economics and clinical performance, reduced disease transfer risk and absence of cultural constraints on usage.
MAX Endoscopy
MAX Endoscopy designs and manufactures innovative endoscopic accessory devices that fill unmet needs in the field of Gastrointestinal (GI) endoscopy.
-
MenRx Surgical LLC
MenRx Surgical markets the Pro-Vas Occlusion Device which provides men seeking a permanent form of contraception with a less-invasive alternative to vasectomy.
-
NuVue Therapeutics, Inc.
Biotechnology-driven, medical device company that has developed, and brings to market, a totally new and innovative image-guided, site-specific, drug and cryothermally mediated, regimen of cancer therapy for soft tissue tumors.
Olive Medical Corp.
Developed industry's first "Single-Use" High Definition (HD) surgical camera that will provide high quality HD imaging at a fraction of the price of current market leading HD cameras.
OvaTech, Inc.
Emerging medical technology company that is focused on products to enhance women's health in the contraceptive space.
-
Paramed Srl
Developing an open MRI scanner called MRopen. MRopen 0.5 T uses open-sky superconductive U-shaped magnet with no barriers in between the patient and the environment. The magnet gap of 60 cm enables an easy access and positioning, along with a greater patient acceptance.
-
Prochon Biotech, Ltd.
Novel Fibroblast Growth Factor variants (FGF2v, FGF4v, FGF9v) for therapeutic and reagent/cell expansion applications with a commercial focus on articular cartilage repair and regeneration.
Q-Core, Ltd.
Q-Cor Research, Development, Manufacture and INNOVATION of infusion pump platforms for today and tomorrow’s electronic drug delivery needs.
RepRegen™, Ltd.
Repregen™ is a London-based medical device company that uses patented repair and regeneration technology platforms designed to mend and regrow hard-tissue such as bone and soft-tissue such as cartilage.
Solid-Look Corporation
Solid-Look Corporation is changing the surgical paradigm from 2D to 3D-HD Stereoscopic Vision for Minimally Invasive Surgery offering EndoStereoVision a superior, modular, proprietary, 3D, real time, stereoscopic vision and recording systems.
-
Sphere Medical, Ltd.
Monitoring products based on microsensor technology allowing minimally invasive, real time measurement of clinical chemistry parameters and therapeutic drug concentrations.
-
ThermopeutiX, Inc.
THERMOPEUTIX, INC has developed a proprietary catheter system/ treatment for ischemic brain injury. Primary markets are cardiac arrest, acute stroke and trauma.
Valam Corp.
Proving the clinical and quality-of-life benefits of cost-effective, laser-based antimicrobial treatments for Chronic Rhinosinusitis (CRS).
Valentine Vascular, Inc.
Valentine Vascular, Inc. (VV) is an early-stage medical device company specializing in the use of bioceramics for the treatment of post myocardial infarctions, mitral valve regurgitation, applications to coronary and peripheral stents, and other technologies in development.
-
Brochure Download
Get event information in a convenient PDF format.

-
IN3 Europe 2010
Audio Session
Listen to key plenary session topics.
-
IN3 West 2010
Proceedings Book
Get event information in a convenient PDF format.

-
IN3 West 2010
Audio Session
Listen to key plenary session topics.
-
IN3 West 2010
Session Slides
View Investor Day VC presentations.
-
IN3 Europe 2009
Audio Session
Listen to key plenary session topics.
-
IN3 Summit 2009
Audio Session
Listen to key plenary session topics.
-
IN3 Europe Video
Get 'behind the scenes' info on this event.
-
IN3 East Video
Get 'behind the scenes' info on this event.
-

October 27-29, 2010
San Francisco, CA - USA
-
.jpg)
Spring 2011
Las Vegas, NV - USA
-

Spring 2011
Paris, France
| IN3 Investor Day - June 9 |
IN3 Main Event - June 10-11 |
| Investor Day is a must-attend if you are interested in what investment leaders in the industry are thinking, doing, and planning. Noteworthy venture capitalists and corporate acquirers address what interests them most in innovative technologies, therapeutic areas, products, and geographic markets. They will also discuss partnering opportunities, how to maximize visibility in front of large company investors, and the role of M&A. |
The Main Event is designed for those in the business development and/or financial community who are interested in investment or partnering opportunities with medtech innovators. Medtech innovators give 10-minute presentations on their latest medical device innovations within a wide range of high-growth markets. In between presentation blocks, enjoy dedicated break-out sessions for one-on-one meetings, and networking. |
"This conference afforded me the chance to sit down not only with three major multinational companies but also attract the attention of other quality investors whom I might not have met otherwise," said Ian Brown, CEO of RepRegen™. "This is my first IN3 event, and I believe these meetings offer emerging companies a great value for getting in front of quality investors."
- Nearly 50 presentations by medical technology innovators with the most desired technologies.
- 20+ finance presentations and perspectives by some of the industry's biggest players.
- Over two dozen networking opportunities.
- Partnering Software to identify attendees and plan private, 1-on-1 meetings in advance – all without schedule overlap or program interrupt.
- Multiple keynote plenary panels on the latest 'deals' case studies, device investing, M&A, health reform, clinicians, and more!
- Access to current and future news on investing and partnering, as driven by Elsevier Business Intelligence researchers, analysts, and authors.
Over 1,500 emerging medical technology company presenters and more than 8,000 attendees have participated at IN3 events over the past nine years. We are very proud to say that many young companies have worked their way up the funding ladder and into the marketplace via the relationships they formed at IN3 events. Click Here for success stories and testimonials from our past presenters and attendees.

Click Title for More Info
| Why Use Windhover Conferences Partnering Software? |
- • Identify attendees to choose potential partners.
- • Search database of partnering/investing opportunities(including deal history and related articles).
- • Communicate and pre-schedule as many meetings as you wish with fellow attendees.
- • Showcase your company's innovative technology and investment/partnering interests.
|
For more information, please contact:
Kristy Kennedy at 1-480-985-9512 or Kayleen Kell at 1-888-290-2225 (USA only), or email IN3@Elsevier.com.
Important Deadlines |
| Save $100 before: |
EXPIRED |
| Last Chance for Discounted Rooms (may sell out earlier) |
EXPIRED |
| Partnering Opens (start scheduling meetings) |
EXPIRED |
| Innovator Company Profile Due |
EXPIRED |
Click Here to view full pricing schedule.
Who Attends
- • Presidents, CEOs, CTOs, COOs
- • Founders, Chairpersons
- • Venture Partners
- • Managing Directors
- • VPs/Directors of Strategic Planning, Business Development, Marketing, New Technology, Acquisitions, R&D, & Sales
- • Senior Investment
- • Analysts/Principals/Directors
- • Established device companies seeking technology via licensing, partnering, and acquisition to broaden or deepen product lines or build sector strength.
- • VCs and investment bankers.
- • Medical device, biopharmaceutical, biotech, or other company executives seeking investments or partnerships.
Benefits of Attending
Potential acquirers/funding partners can meet and screen over 50 hand-selected, first-rate investment possibilities in just two well-orchestrated days, via focused presentations covering widely varied technologies, stages of development and testing, potential markets, management teams, regulatory timeline, patent protection, competitive strategy, funding desired, and much more... Including private break-out sessions and networking events.
Medical device start-ups face intense competition for a finite amount of available capital funding. This makes IN3 events the ideal setting for emerging companies to meet and impress potential investors from many of the top-tier device companies and discerning healthcare investment firms from around the world.
All attendees will gain a keen under-standing (in a short timeframe) of the emerging medical technologies that are on track to make a distinct impact on the intensely-competitive device industry.
Advisory Board
- Annette Campbell-White
Senior Managing Member
MedVenture Associates
- Michael Carusi
General Partner
Advanced Technology Ventures
- Luke Evnin
General Partner
MPM Capital
- Richard M. Ferrari
Managing Director
DeNovo Ventures
- William T. Harrington
Partner
Three Arch Partners
- Ross A. Jaffe
Managing Director
Versant Ventures
- Josh Makower
Venture Partner
NEA
- John Maroney
General Partner
Delphi Ventures
- Allan May
Chairman, Founder
Life Science Angels
Managing Director
Emergent Medical Partner
- David Milne
Managing Partner
SV Life Science Advisers
- Trevor J. Moody
Partner
Frazier Healthcare Ventures
- Jesse I Treu
Partner
Domain Associates
|
|